TrialTargeted oncology2022

A Phase IIIb Open-Label, Single-Arm Study of Afatinib in EGFR TKI-Naïve Patients with EGFRm+ NSCLC: Final Analysis, with a Focus on Patients Enrolled at Sites in China.

Hai-Yan Tu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.